https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49803 38 years (1.34; 1.04–1.73); those with disease duration > 7 years (1.33; 1.01–1.74); those with EDSS score < 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.]]> Wed 31 May 2023 15:59:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45667 Wed 02 Nov 2022 15:59:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51272 Tue 29 Aug 2023 15:42:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53300 Tue 21 Nov 2023 12:02:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52249 Thu 05 Oct 2023 14:07:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49695 Mon 29 May 2023 12:46:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41847 p = 0.010); but no differences in spontaneous abortions, term or preterm births. Conclusions: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.]]> Mon 15 Aug 2022 10:27:59 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53931 Fri 22 Mar 2024 08:23:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41083 Fri 22 Jul 2022 17:11:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53317 Fri 19 Jan 2024 14:25:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>